Lipodystrophy mice are resistant to anti-diabetic effects of recombinant FGF21 treatment.

<p>Recombinant muFGF21 (1 or 10 mg/kg, pink and red symbols respectively) or vehicle (green symbols) was injected BID in wildtype (WT - open bars) and aP2-nSrebp1c lipodystrophy (Tg - hatched bars) male mice as described in Animal Study Design I (Methodology). (A–B) Body weight was monitored daily. Dramatic drop in body weight on day 17 was caused by the 12 h fast for GTT. (C–D) Adipose and lean mass was recorded in WT and Tg mice at 0, 7 and 14 days of treatment. (E–F) Fed blood glucose (OneTouch Basic glucometer) and plasma insulin were measured in WT and Tg mice at the start (PRE) and the end (POST) of the treatment. (G–H) Glucose tolerance was measured on day 18 of treatment (OneTouch Basic glucometer). (I) Area under the curve (AUC) was calculated in WT and Tg mice. (J–L) Plasma lipids (cholesterol, triglycerides, NEFA – non-esterified fatty acids) were measured in WT and Tg mice at the start (PRE) and the end (POST) of the treatment. WT groups N = 8; Tg vehicle group N = 8; Tg FGF21 treatment group N = 7. * <i>P</i><0.05, ** <i>P</i><0.01, *** <i>P</i><0.001 <i>vs.</i> vehicle-treated genotype-matched mice at same time point, ns – not statistically significant. ++ <i>P</i><0.01, +++ <i>P</i><0.001 <i>vs.</i> WT mice (T-Test).